Dosage and Administration

Product Profile Aggrenox®

• Approved for prevention of stroke in patients who have suffered a recent stroke or TIA
• New formulation provides extended-release and uniform levels of drug delivery over 12-hour period
• Prevents twice as many recurrent strokes as ASA
• Superior relative risk reduction compared to clopidogrel (indirect comparison)
• No increase in bleeding when compared with low dose ASA
• Recommended above clopidogrel in main European (ESO and NICE) and US (AHA/ASA and ACCP) evidence-based treatment guidelines